


REMAP-CAP



IN THIS ISSUE

- A Warm Welcome to New Sites
- Recruitment Update
- Closed domain: ACE2RAS
- Featured domain: Cysteamine
- New domain: Endothelial
- ACTA Award Australia
- WE4YOU

A WARM WELCOME

Since our last issue we added two sites to the [#remapcapfamily](#)

- IRCC Ca' Granda Ospedale Maggiore Policlinico di Milano (Italy)
- Ospedale Infermi di Rimini (Italy)



RECRUITMENT UPDATE

As of 26 June 2022, REMAP-CAP is active in **332** sites in **21** countries worldwide and a total of **11,433** unique patients have been included, of which **9,900** are patients with suspected or proven covid-19. These patients contributed to a total of **20,262** randomisations in the different domains.

Europe:

- **217** Activate Sites
- **7,024** Patient Inclusions
- **6,704** patients with suspected/proven covid-19
- **13,264** Randomisations

Dear REMAP-CAP investigators,

Covid-19 is (still) not gone, and many countries are seeing more hospitalizations currently.

ICU admissions are low, and we hope they remain low, but let's aim to learn from those that do need hospital or ICU admission: randomize them to REMAP-CAP!

We continue to develop domains for answering urgent clinical questions for our patients, so we can keep learning together.

In the background, our EU and global teams are identifying what we have learned in the pandemic, to build an even better, sustainable, well organized platform for our ongoing research.

For now, I hope you all have a great summer, and I wish you relaxing and inspiring holidays.

On behalf of the REMAP-CAP team,
Lennie Derde

Global Chair of the International Trial Steering Committee
European Coordinating Investigator



REMAP-CAP ITSC at CCR22 in Belfast

ACTA AWARD AUSTRALIA

We congratulate Steve Webb, Lisa Higgins, Aidan Burrell, Cameron Green, and the Australian team with winning the **Trial of the Year Award** from the Australian Clinical Trials Alliance!



Click [here](#) to read more.

ON-SITE VISITS IN SPAIN

Project managers Albertine and Janine visited Spanish sites in Cordoba and Tortosa (see picture below). It was a pleasure to meet the staff in Spain and Albertine and Janine felt very welcome.



NEW DOMAIN: ENDOTHELIAL

We are pleased to announce recent finalization of the Endothelial DSA. The objective of this domain is to determine the effectiveness of interventions that modulate endothelial function for patients with severe community acquired pneumonia, including proven or suspected covid-19 or influenza or both.

Please [email](#) if interested in this domain.

DOMAIN CLOSED: ACE2RAS

The ITSC has recently decided to formally close recruitment of Moderate State patients to the ACE2RAS Domain to allow for the results of this domain to be analyzed and reported.

Read the ITSC letter to REMAP-CAP sites [here](#).

COLLABORATIVE MONITORING

Over 140 sites were opened in the UK since the beginning of the pandemic, so project managers Clementina and Sara worked together with the UK team to perform monitoring visits together.



FEATURED DOMAIN: CYSTEAMINE

The REMAP-CAP Cysteamine domain was released in June of 2021. This domain was first implemented in the United Kingdom and is now available for implementation at all sites in Europe.

The objective of this domain is to determine the effectiveness of cysteamine in patients with severe pneumonia. Patients are randomized to receive no cysteamine (no placebo) or cysteamine every 8 hours at a dose of 5mg/kg with a maximum dose of 500 mg. The duration of treatment is 10 days or until hospital discharge, whichever occurs first.

Cysteamine will be provided by the sponsor in collaboration with NovaBiotics. The drug is provided frozen in packages of 20cm (L) x 7cm (W) x 7cm (H) per patient. Once taken out of the freezer, it can be stored refrigerated during the 10-day treatment period.

Please [email](#) the sponsor team if you are interested in participating in the cysteamine domain.